Jill Marie Broadfoot
Known title: DirectorCIK: 0001305178
Jill Marie Broadfoot's purchase track record
Jill Marie Broadfoot has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/31/2024 | ATYR | $9K | +8.1% | +104.0% | +14.3% |
| 1/13/2022 | ATYR | $13K | -26.0% | -54.7% | -18.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TLPH | ▲ Buy | Grant | 5,100 | $0 | 6/22/2026 | View on chart |
| ATYR | ▼ Sell | Open Market | 1,558 | $2K | 2/4/2026 | View on chart |
| ATYR | ▲ Buy | Option Exercise | 3,750 | — | 2/3/2026 | View on chart |
| TLPH | ▲ Buy | Grant | 4,267 | $0 | 10/23/2025 | View on chart |
| ATYR | ▼ Sell | Open Market | 1,254 | $5K | 2/4/2025 | View on chart |
| ATYR | ▲ Buy | Option Exercise | 3,750 | — | 2/3/2025 | View on chart |
| TLPH | ▲ Buy | Grant | 2,174 | $0 | 6/24/2024 | View on chart |
| ATYR | ▲ Buy | Open Market | 5,000 | $9K | 5/31/2024 | View on chart |
| ATYR | ▼ Sell | Open Market | 1,590 | $3K | 2/6/2024 | View on chart |
| ATYR | ▲ Buy | Option Exercise | 3,750 | — | 2/5/2024 | View on chart |
| TLPH | ▲ Buy | Grant | 581 | $0 | 10/10/2023 | View on chart |
| ATYR | ▼ Sell | Open Market | 1,566 | $4K | 2/6/2023 | View on chart |
| ATYR | ▲ Buy | Option Exercise | 3,750 | — | 2/3/2023 | View on chart |
| TLPH | ▲ Buy | Grant | 15,500 | $0 | 7/15/2022 | View on chart |
| ATYR | ▲ Buy | Open Market | 1,923 | $13K | 1/13/2022 | View on chart |
| TLPH | ▲ Buy | Grant | 15,000 | $0 | 11/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
aTyr Pharma Aligns With FDA On Phase 3 Efzofitimod Plan
aTyr Pharma announced it has reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. The company expects to begin study-related activities in the fourth quarter of 2026. This regulatory progress follows a period where the stock traded near its 52-week low, indicating a significant step in the drug's development timeline.
aTyr Pharma Aligns With FDA On Phase 3 Efzofitimod Plan. aTyr Pharma announced it has reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. The company expects to begin study-related activities in the fourth quarter of 2026. This regulatory progress follows a period where the stock traded near its 52-week low, indicating a significant step in the drug's development timeline.